A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial
Latest Information Update: 22 Sep 2026
At a glance
- Drugs Retatrutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms TRIUMPH-2
- Sponsors Eli Lilly and Company
Most Recent Events
- 15 Sep 2026 According to Eli Lilly and Company media release, the data from the trial will be presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD)
- 15 Sep 2026 Results presented in the Eli Lilly and Company media release.
- 30 Jul 2026 Status changed from active, no longer recruiting to completed.